Holen Sie sich die Stockscreener-App
2.67
2.69%
0.07
Schlusskurs vom Vortag:
$2.60
Offen:
$2.49
24-Stunden-Volumen:
15,283
Relative Volume:
0.08
Marktkapitalisierung:
$30.81M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-3.15M
KGV:
-8.7484
EPS:
-0.3052
Netto-Cashflow:
$-2.23M
1W Leistung:
-3.96%
1M Leistung:
+6.80%
6M Leistung:
+78.00%
1J Leistung:
+28.99%
1-Tages-Spanne:
$2.49
$2.80
1-Wochen-Bereich:
$2.42
$2.80
52-Wochen-Spanne:
$1.20
$4.0499
Cytomed Therapeutics Ltd Stock (GDTC) Company Profile
Firmenname
Cytomed Therapeutics Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie GDTC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GDTC
Cytomed Therapeutics Ltd
|
2.67 | 30.81M | 0 | -3.15M | -2.23M | -0.3052 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Cytomed Therapeutics Ltd Aktie (GDTC) Neueste Nachrichten
CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration - ACCESS Newswire
CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders - Marketscreener.com
SunAct Cancer Institute and CytoMed begin phase 2 trials for Gamma Delta T-cell therapy - Express Healthcare
CytoMed Therapeutics (NASDAQ:GDTC) Shares Down 13.7% – Here’s What Happened - Defense World
CytoMed and SunAct Collaborate on Cancer Immunotherapy Trials in India - Yahoo Finance
CytoMed Therapeutics and SunAct to conduct solid tumour treatment trial in India - Yahoo Finance
SunAct & CytoMed join hands for Ph 2 clinical trials of innovative cancer therapy in India - BSA bureau
Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor - Benzinga
CytoMed Therapeutics Limited Signs Business & Research Collaboration Agreement with Sunact Cancer Institute Private Limited to Advance Use of Allogeneic Off-The-Shelf Gamma Delta T Cells for Treatment of Solid Cancers in Proposed Phase 2 Clinical Tr - Marketscreener.com
CytoMed and SunAct partner for cancer immunotherapy trials - Investing.com
CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in - Marketscreener.com
CytoMed Therapeutics Leads 3 US Penny Stocks To Consider - Simply Wall St
CytoMed Therapeutics Limited Announces Resignation of Dr Tan Wee Kiat as Co-Chief Executive Officer, Effective December 31, 2024 - Marketscreener.com
CytoMed Therapeutics Limited Announces Resignation of Dr Tan Wee Kiat as Director and Chief Operating Officer, Effective December 31, 2024 - Marketscreener.com
CytoMed Therapeutics : Organisation and personnel changes Form 6 K - Marketscreener.com
CytoMed Therapeutics And 2 Other US Penny Stocks To Watch - Simply Wall St
CytoMed Therapeutics : Update on Clinical Milestone CytoMed Therapeutics Announces First Patient Dosed in its First in Human Phase I Clinical Trial of Allogeneic CAR Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematologica - Marketscreener.com
CytoMed Therapeutics Limited Announces First Patient Dosed in Its First-In-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies - Marketscreener.com
Update on Clinical MilestoneCytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies - GlobeNewswire
Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap - Simply Wall St
Osteopore partners with NASDAQ-listed CytoMed to advance MSC-powered regeneration - Biotech Dispatch
Osteopore Partners with CytoMed in Regenerative Medicine - TipRanks
CytoMed begins clinical trial for innovative cancer therapy - Investing.com
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank - Marketscreener.com
Cytomed Therapeutics announces NMRC co-funding support for ANGELICA trial - TipRanks
CytoMed Launches Innovative CAR-T Cell Trial - TipRanks
CytoMed begins clinical trial for innovative cancer therapy By Investing.com - Investing.com South Africa
CytoMed Therapeutics’ first-in-human Phase I ANGELICA - GlobeNewswire
CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant - StockTitan
CytoMed Acquires Cord Blood Assets, Eyes Regenerative Medicine - Yahoo Finance
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed's strategy to cord blood-derived biologics through subsidiary, LongevityBank - The Manila Times
CytoMed Therapeutics completes cash acquisition of Cord - GlobeNewswire
GDTCCytoMed Therapeutics Limited Ordinary Shares Latest Stock News & Market Updates - StockTitan
CYTOMED THERAPEUTICS : AND SUBSIDIARIES UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Form 6 K - Marketscreener.com
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 - GlobeNewswire
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates - Yahoo Finance
Presenting on the Emerging Growth Conference 75 Day 2 on September 26 - GlobeNewswire
Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now - GlobeNewswire
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers - GlobeNewswire
Emergence of Cell and Gene Therapy Community in Singapore - BSA bureau
Anti-aging Therapeutics Market Size, Scope, Growth and Forecast to 2031 - InsightAce Analytic
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies - Marketscreener.com
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair - GlobeNewswire
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology - Yahoo Finance
GDTC Stock Price and Chart — NASDAQ:GDTC - TradingView
CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology - PR Newswire
CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update - PR Newswire
Cytomed Therapeutics Limited (GDTC-Q) QuotePress Release - The Globe and Mail
CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency - PR Newswire
CytoMed Therapeutics Granted Patent in China for Licensed Allogeneic CAR-Gamma Delta T Cell Technology - Investing.com South Africa
Novel T-Cell Immunotherapies Market Share, Size, Growth and Forecast to 2031 - InsightAce Analytic
Finanzdaten der Cytomed Therapeutics Ltd-Aktie (GDTC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.39%
0.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):